JP2025500796A5 - - Google Patents

Info

Publication number
JP2025500796A5
JP2025500796A5 JP2024534342A JP2024534342A JP2025500796A5 JP 2025500796 A5 JP2025500796 A5 JP 2025500796A5 JP 2024534342 A JP2024534342 A JP 2024534342A JP 2024534342 A JP2024534342 A JP 2024534342A JP 2025500796 A5 JP2025500796 A5 JP 2025500796A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081076 external-priority patent/WO2023107994A1/en
Publication of JP2025500796A publication Critical patent/JP2025500796A/ja
Publication of JP2025500796A5 publication Critical patent/JP2025500796A5/ja
Pending legal-status Critical Current

Links

JP2024534342A 2021-12-08 2022-12-07 抗変異体カルレチクリン(calr)抗体及びその使用 Pending JP2025500796A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163287394P 2021-12-08 2021-12-08
US63/287,394 2021-12-08
US202163288479P 2021-12-10 2021-12-10
US63/288,479 2021-12-10
US202263421052P 2022-10-31 2022-10-31
US63/421,052 2022-10-31
PCT/US2022/081076 WO2023107994A1 (en) 2021-12-08 2022-12-07 Anti-mutant calreticulin (calr) antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025500796A JP2025500796A (ja) 2025-01-15
JP2025500796A5 true JP2025500796A5 (cg-RX-API-DMAC7.html) 2026-04-08

Family

ID=84943209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534342A Pending JP2025500796A (ja) 2021-12-08 2022-12-07 抗変異体カルレチクリン(calr)抗体及びその使用

Country Status (19)

Country Link
US (1) US20230272055A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444343A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025500796A (cg-RX-API-DMAC7.html)
KR (1) KR20240127992A (cg-RX-API-DMAC7.html)
AU (1) AU2022407445A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241889A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024001654A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024009042A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240277A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000110A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416555A (cg-RX-API-DMAC7.html)
IL (1) IL313366A (cg-RX-API-DMAC7.html)
JO (1) JOP20240122A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024006954A (cg-RX-API-DMAC7.html)
PE (1) PE20241998A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330623A (cg-RX-API-DMAC7.html)
UY (1) UY40062A (cg-RX-API-DMAC7.html)
WO (1) WO2023107994A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202404295B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
WO2025096716A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof
WO2026013015A1 (en) * 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026136827A1 (en) 2024-12-20 2026-06-25 Incyte Corporation Treatment of clonal hematopoietic disorders using kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP2448938B9 (en) 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinones as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3932952A4 (en) 2019-02-28 2022-11-30 Juntendo Educational Foundation ANTIBODIES BINDING TO TRUNKED MUTANT CALRETICULIN AND DIAGNOSTIC, PROPHYLACTIC OR THERAPEUTIC DRUG FOR MYELOPROLIFERATIVE NEOPLASMA

Similar Documents

Publication Publication Date Title
JP6709215B2 (ja) 抗tim−3抗体
JP6719477B2 (ja) 抗tim−3抗体
Beiboer et al. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent
JP6743320B1 (ja) 抗cd137抗体
JP2021532058A5 (cg-RX-API-DMAC7.html)
JP2019527553A5 (cg-RX-API-DMAC7.html)
JP7649744B2 (ja) Btn3a結合タンパク質及びその使用
JP2021524478A5 (cg-RX-API-DMAC7.html)
WO2014089209A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP2015502145A5 (cg-RX-API-DMAC7.html)
JP2021530244A5 (cg-RX-API-DMAC7.html)
WO2015191934A2 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2023520969A5 (cg-RX-API-DMAC7.html)
JP2023509390A5 (cg-RX-API-DMAC7.html)
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
JP2021529776A5 (cg-RX-API-DMAC7.html)
JP2025505650A5 (cg-RX-API-DMAC7.html)
JP2023536631A5 (cg-RX-API-DMAC7.html)
JP2023518225A5 (cg-RX-API-DMAC7.html)
JP2024509501A5 (cg-RX-API-DMAC7.html)
JP2022513437A5 (cg-RX-API-DMAC7.html)
JP2022531552A5 (cg-RX-API-DMAC7.html)
JP2020515286A5 (cg-RX-API-DMAC7.html)
WO2025213712A1 (zh) 基于ai从头设计筛选合成的her2蛋白特异性结合抗体及其应用
TWI889766B (zh) 抗cd19抗體以及使用與製造其的方法